RecruitingNot ApplicableNCT06617013
GERD in Children With Cystic Fibrosis
Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis
Sponsor
Duke University
Enrollment
20 participants
Start Date
Oct 23, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
Eligibility
Min Age: 2 YearsMax Age: 18 Years
Inclusion Criteria2
- Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
- Signed consent
Exclusion Criteria3
- Declining to participate in the study or sign consent
- History of severe GERD per gastroenterology diagnosis and documentation
- GSAS score \>80
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERDiscontinuation of GERD therapy
GERD therapy will be discontinued at time of enrollment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06617013
Related Trials
Physical Impairments in Children With Cystic Fibrosis
NCT069846791 location
19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
NCT060667231 location
Sinus Disease in Young Children With Cystic Fibrosis
NCT061916406 locations
Feasibility of Cough Monitoring in Children
NCT065871261 location
Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis
NCT062845771 location